Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study)

The French healthcare system is a universal healthcare system with no financial barrier to access to health services and cancer drugs. The objective of the study is to investigate associations between, on the one hand, incidence and survival of patients diagnosed with lung cancer in France and, on t...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 12; no. 8; p. e0182798
Main Authors Chouaïd, Christos, Debieuvre, Didier, Durand-Zaleski, Isabelle, Fernandes, Jérôme, Scherpereel, Arnaud, Westeel, Virginie, Blein, Cécile, Gaudin, Anne-Françoise, Ozan, Nicolas, Leblanc, Soline, Vainchtock, Alexandre, Chauvin, Pierre, Cotté, François-Emery, Souquet, Pierre-Jean
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 25.08.2017
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The French healthcare system is a universal healthcare system with no financial barrier to access to health services and cancer drugs. The objective of the study is to investigate associations between, on the one hand, incidence and survival of patients diagnosed with lung cancer in France and, on the other, the socioeconomic deprivation and population density of their municipality of residence. A national, longitudinal analysis using data from the French National Hospital database crossed with the population density of the municipality and a social deprivation index based on census data aggregated at the municipality level. For lung cancer diagnosed at the metastatic stage, one-year and two-year survival was not associated with the population density of the municipality of residence. In contrast, mortality was higher for people living in very deprived, deprived and privileged areas compared to very privileged areas (hazard ratios at two years: 1.19 [1.13-1.25], 1.14 [1.08-1.20] and 1.10 [1.04-1.16] respectively). Similar associations are also observed in patients diagnosed with non-metastatic disease (hazard ratios at two years: 1.21 [1.13-1.30], 1.15 [1.08-1.23] and 1.10 [1.03-1.18] for people living in very deprived, deprived and privileged areas compared to very privileged areas). Despite a universal healthcare coverage, survival inequalities in patients with lung cancer can be observed in France with respect to certain socioeconomic indicators.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: C Chouaïd has received honoraria and compensation for meeting expenses from Astra Zeneca, Boehringer Ingelheim, MSD, Pierre Fabre Oncology, Lilly, Roche, Bristol-Myers Squibb, Novartis, Lilly, Pierre Fabre Oncology and Boehringer Ingelheim. PJ Souquet has received honoraria or compensation for meeting expenses from Amgen, Astellas, Astra Zeneca, Bayer, BMS, Boehringer Ingelheim, Chugai, Lilly, Novartis, Pierre Fabre Oncologie, Pfizer, Roche and Sandoz. I Durand-Zaleski has received consultancy fees from Bristol-Myers Squibb for her participation in scientific committees, and from Abbvie, Amgen, Janssen, MSD and Pfizer for her participation in educational seminars. J Fernandes, D Debieuvre and P Chauvin have received consultancy fees from Bristol-Myers Squibb. A Scherpereel has participated in several expert boards for Bristol-Myers Squibb, Roche, MSD and AZ-MedImmune, and has received research grants from Teva and Pierre Fabre. V Westeel has received honoraria from Astra Zeneca, Boehringer Ingelheim, MSD, Pierre Fabre Oncology, Lilly, Roche, Bristol-Myers Squibb, and Novartis and compensation for meeting expenses form Lilly, Merck Serono, Novartis, Pierre Fabre Oncology and Boehringer Ingelheim. C Blein, S Leblanc and A Vainchtock have received research grants from Bristol-Myers Squibb, sponsor of the study. AF Gaudin, N Ozan and FE Cotté are salaried employees of Bristol-Myers Squibb, sponsor of the study. The above potential conflicts of interest do not alter the adherence of any of the authors to PLOS ONE policies on sharing data and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0182798